Stock Taper
SCREENER COMPARE ANY 2 STOCKS
CRSP
CRISPR THERAPEUTICS AG
NASDAQ
$57.72
▼ DOWN 2.78% (-1.65)

KEY STATISTICS

Market Cap$5.57 B
52w High$78.48
52w Low$44.12
Dividend Yield—
Frequency—
P/E-12.13
Volume1.39M
Shares Out.96.45M

COMPANY

LEADERSHIP

Samarth Kulkarni
CHIEF EXECUTIVE
Samarth Kulkarni

ABOUT

SECTOR
Healthcare
WENT PUBLIC
October 19, 2016
METHOD OF GOING PUBLIC
IPO
FULL TIME EMPLOYEES
393

PRICE TARGET

Target High$80.00
Target Low$55.00
Target Median$68.00
Target Consensus$67.83

UPCOMING EARNINGS

DateNov 9, 2026
DayMonday
Rev. Est.$14.84M
NOV
9
MON

PRICE

$57.72 ▼ DOWN 2.78% (−$1.65)
$57.75$58.50$59.259:30 AM10:35 AM11:40 AM12:45 PM1:49 PM2:54 PM3:59 PM57.72

About CRISPR Therapeutics AG

https://www.crisprtx.com ↗

CRISPR Therapeutics develops gene-based medicines using CRISPR/Cas9, with programs targeting diseases like beta-thalassemia, sickle cell, cancers, and diabetes. Key products include CTX001 and various CAR-T therapies.

INDUSTRY

Biotechnology

A PRODUCT CRISPR THERAPEUTICS AG IS KNOWN FOR

Casgevy
Casgevy

Casgevy, the first CRISPR/Cas9 gene-edited therapy, treats sickle cell disease and beta-thalassemia, marking a milestone and offering a potential cure for these inherited blood disorders.

COMPETITORS

COMPETITOR
BEAM COMPARE
EDIT COMPARE
NTLA COMPARE
VRTX COMPARE

Revenue by Products

IconPRODUCTQ3-2025Q4-2025Q1-2026Q2-2026
Collaboration Revenue— — $1M $10M ▲
Grant$889K $864K ▼$458K ▼$181K ▼

ETFS HOLDING THIS STOCK

ETFS HOLDING
154
LISTED HERE
26
RANKED BY POSITION SIZE
ARKK
4.77% · 5.3M
IWM
0.18% · 2.4M
XBI
1.07% · 2.1M
VXF
0.06% · 1.1M
SCHA
0.12% · 459.1K
AVSC
0.29% · 151.4K
FESM
0.08% · 89.6K
XRS2.DE
0.17% · 85.1K
LABU
0.73% · 77.9K
GNOM
3.01% · 48.4K
NXTE
3.36% · 30.7K
BBP
1.46% · 29.4K
JHSC
0.23% · 28.2K
BBSC
0.21% · 26.9K
HTEC
1.67% · 22.0K
CN
CNCR
3.39% · 12.6K
FSCC
0.20% · 11.6K
GSSC
0.06% · 10.7K
WBIO.L
1.63% · 9.3K
MEDX
2.80% · 8.3K
PDN
0.11% · 6.5K
HELX
0.98% · 5.4K
TILT
0.01% · 5.4K
URTY
0.07% · 3.8K
STXK
0.25% · 3.7K
VETS
0.24% · 1.4K

INSTITUTIONAL OWNERSHIP

SHARES OWNED
59.53%
HOLDERS
725
TOP 12 OF 725 · RANKED BY POSITION SIZE
Ark Investment Management LLC
11.3M sh · $538.19M
Blackrock, Inc.
8.3M sh · $455.35M
Orbis Allan Gray Ltd
6.1M sh · $290.46M
Capital International Investors
5.9M sh · $309.02M
Capital World Investors
4.7M sh · $259.04M
State Street Corp
4.3M sh · $235.7M
T. Rowe Price Investment Management, Inc.
3.3M sh · $212.75M
Gsk Plc
3.2M sh · $153.21M
Blackrock Inc.
2.8M sh · $150.03M
Ubs Group AG
2.5M sh · $132.37M
Geode Capital Management, LLC
2.5M sh · $136.92M
Vanguard Group Inc
2.4M sh · $153.25M

RATINGS SNAPSHOT

Overall rating: C-

DCFROEROAD/EP/EP/B
Discounted Cash Flow1
Return On Equity1
Return On Assets1
Debt To Equity2
Price To Earnings1
Price To Book2
Overall Score1

TRADES BY CONGRESS

HOUSE TRADES
Thomas Suozzi
Thomas Suozzi
Sale (Full)
2021-09-20
 Marjorie Taylor Greene
Marjorie Taylor Greene
Purchase
2021-01-21
SENATE TRADES
James Inhofe
James Inhofe
Sale (Partial)
2021-01-05

INSIDER TRADES

★
OFFICER: CHIEF FINANCIAL OFFICER
Prasad Raju
Sale · 750 shares
2026-08-07
★
DIRECTOR
Morrison Briggs
Purchase · 13.0K shares
2026-06-05
★
DIRECTOR
Mahatme Sandesh
Purchase · 13.0K shares
2026-06-05
★
DIRECTOR
Rommel Christian
Purchase · 13.0K shares
2026-06-05

MOST RECENT ANALYST GRADES

GRADE SUMMARY
BUY 5
MARKET OUTPERFORM 1
MARKET PERFORM 1
OVERWEIGHT 1
HOLD 1
OUTPERFORM 1
NEUTRAL 1
SECTOR PERFORM 1
12 GRADES IN THE LAST 12 MONTHS
Citizens MARKET OUTPERFORM Citigroup BUY HC Wainwright & Co. BUY Bernstein MARKET PERFORM Piper Sandler OVERWEIGHT Chardan Capital BUY TD Cowen HOLD Needham BUY

SECTORS PEERS

PEERPRICE
ARWR$84.91COMPARE
KRYS$351.46COMPARE
CYTK$72.09COMPARE
PCVX$59.84COMPARE
TGTX$53.93COMPARE
PTCT$70.09COMPARE